An anonymous donor made a $50 million gift to Duke University Health System toward the development of a proton beam therapy center. The donation is the largest philanthropic gift received by Duke University Health System.
Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.
CureSearch for Children’s Cancer awarded a $225,000 research grant to John Prensner, a physician-scientist at the University of Michigan, to advance research on atypical teratoid/rhabdoid tumors. One of the most aggressive and fatal brain cancers affecting infants and toddlers, ATRT has limited treatment options and devastating outcomes, with more than half of cases proving fatal.
The Association of Cancer Care Centers Board of Trustees released the following statement regarding the firefighters currently battling wildfires in Los Angeles County:
A recent report showed that UPMC Hillman Cancer Center generated $3.98 billion in total economic impact in Pennsylvania through its clinical, research, and educational missions in 2023. Â
The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.Â
Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers. Â
OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.
Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.
